| Respiratory Tract Neoplasms |
ICTAN, NCT01996098: Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation |
|
|
| Recruiting | 3 | 318 | RoW | 6-month Icotinib, BPI-2009, Conmana, 12-month icotinib | Sun Yat-sen University | Lung Cancer | 01/20 | 01/23 | | |
NCT02001168: Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB |
|
|
| Active, not recruiting | 3 | 392 | RoW | Pemetrexed, Alimta, Docetaxel, Taxotere, rh-Endostatin, Endostar, Cis-platinum, Platinol | Xinjiang Medical University | Non-small Cell Lung Cancer | 12/20 | 10/22 | | |
EMERGING, NCT01407822: Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2/3 | 72 | RoW | Erlotinib, Tarceva, Gemcitabine/cisplatin, Gemzar/cisplatin | Guangdong Association of Clinical Trials, Guangdong Provincial People's Hospital, Tianjin Medical University Cancer Institute and Hospital, Jilin Provincial Tumor Hospital, Jiangsu Cancer Institute & Hospital, Zhejiang Cancer Hospital, Peking University Cancer Hospital & Institute, Sun Yat-sen University, West China Hospital, The First Affiliated Hospital of Dalian Medical University, Peking University People's Hospital, Health Science Center of Xi'an Jiaotong University, Shanghai Zhongshan Hospital, Guangzhou General Hospital of Guangzhou Military Command, The First Affiliated Hospital of Guangzhou Medical University, Fujian Medical University Union Hospital, Linyi Tumour Hospital, Northern Jiangsu Province People's Hospital | Non-small Cell Lung Cancer | 04/18 | 12/22 | | |
NCT01731626: Pemetrexed Disodium and Cisplatin in Treating Patients Undergoing Surgery For Stage I-III Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 52 | US | cisplatin, CACP, CDDP, CPDD, DDP, pemetrexed disodium, ALIMTA, LY231514, MTA, laboratory biomarker analysis, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed, fludeoxyglucose F 18, 18FDG, FDG, therapeutic conventional surgery | Roswell Park Cancer Institute, National Cancer Institute (NCI), Eli Lilly and Company | Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | 04/11 | | | |
NCT02254512: METformin With a Cargohydrate Restricted Diet in Combination With Platinum Based Chemotherapy in Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 60 | US | Metformin, Glucophage, Carboplatin, Pemetrexed, Alimta | Beth Israel Medical Center | Carcinoma, Non-squamous Non-small-cell Lung | 06/17 | 09/17 | | |
NCT01588028: A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1/2 | 36 | US | CH5424802 | Hoffmann-La Roche | ALK-Rearranged Non-Small Cell Lung Cancer | 09/15 | 09/15 | | |
|
|
|
NCT00436735: Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors |
|
|
| Active, not recruiting | 1 | 45 | US | midazolam hydrochloride, nelfinavir mesylate, gene expression analysis, polymerase chain reaction, protein expression analysis, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, mass spectrometry | National Cancer Institute (NCI) | Colorectal Cancer, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Islet Cell Tumor, Lung Cancer, Metastatic Cancer, Neuroendocrine Carcinoma of the Skin, Ovarian Cancer, Pheochromocytoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific | | | | |
NCT01279798: Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L) |
|
|
| No Longer Available | N/A | | US | Lucanix® (belagenpumatucel-L), Lucanix | NovaRx Corporation | Non-small Cell Lung Cancer | | | | |
NCT02066883: Prognostic Potential Cell Surface Markers CD47 / CD27 / CD8 and Pim-kinase in Patients With Hematologic Malignancies or Solid Tumors |
|
|
| Recruiting | N/A | 150 | RoW | | Cancer Centre of Monoclonal Therapy, LLC | Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Lymphocytic Leukemia, Burkitt's Lymphoma | 07/15 | 02/17 | | |
NCT02271139: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy |
|
|
| No Longer Available | N/A | | US | Alectinib | Genentech, Inc. | Non-Small Cell Lung Cancer | | | | |
NCT01317953: Oral Green Tea Extract for Small Cell Lung Cancer |
|
|
| Available | N/A | | RoW | epigallocatechin gallate, EGCG | Shandong Cancer Hospital and Institute | Small Cell Lung Carcinoma | | | | |
NCT01595074: Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy |
|
|
| Not yet recruiting | N/A | 950 | Canada | medical chart review, chart review, laboratory biomarker analysis | National Cancer Institute (NCI) | Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer | 01/00 | | | |